Cancer risk in persons with HIV/AIDS in India: a review and future directions for research by Biggar, Bob et al.
BioMed CentralInfectious Agents and Cancer
ssOpen AcceReview
Cancer risk in persons with HIV/AIDS in India: a review and future 
directions for research
Robert J Biggar*1,2, Anil K Chaturvedi3, Kishor Bhatia4 and 
Sam M Mbulaiteye3
Address: 1Dept. of Research, LV Prasad Eye Hospital, Hyderabad, India, 2Department of Epidemiology Research, State Serum Institute, 
Copenhagen, Denmark, 3Infection and Immunoepidemiology Branch, Division of Epidemiology and Genetics, National Cancer Institute, 
Bethesda, Maryland, USA and 4AIDS Malignancy Program, National Cancer Institute, Bethesda, Maryland, USA
Email: Robert J Biggar* - rjbiggar@gmail.com; Anil K Chaturvedi - chaturva@mail.nih.gov; Kishor Bhatia - bhatiak@mail.nih.gov; 
Sam M Mbulaiteye - Mbulaits@mail.nih.gov
* Corresponding author    
Abstract
Background: India has a large and evolving HIV epidemic. Little is known about cancer risk in
Indian persons with HIV/AIDS (PHA) but risk is thought to be low.
Methods: To describe the state of knowledge about cancer patterns in Indian PHA, we reviewed
reports from the international and Indian literature.
Results: As elsewhere, non-Hodgkin lymphomas dominate the profile of recognized cancers, with
immunoblastic/large cell diffuse lymphoma being the most common type. Hodgkin lymphoma is
proportionally increased, perhaps because survival with AIDS is truncated by fatal infections. In
contrast, Kaposi sarcoma is rare, in association with an apparently low prevalence of Kaposi
sarcoma-associated herpesvirus. If confirmed, the reasons for the low prevalence need to be
understood. Cervical, anal, vulva/vaginal and penile cancers all appear to be increased in PHA, based
on limited data. The association may be confounded by sexual behaviors that transmit both HIV
and human papillomavirus. Head and neck tumor incidence may also be increased, an important
concern since these tumors are among the most common in India. Based on limited evidence, the
increase is at buccal/palatal sites, which are associated with tobacco and betel nut chewing rather
than human papillomavirus.
Conclusion: With improving care of HIV and better management of infections, especially
tuberculosis, the longer survival of PHA in India will likely increase the importance of cancer as a
clinical problem in India. With the population's geographic and social diversity, India presents
unique research opportunities that can be embedded in programs targeting HIV/AIDS and other
public health priorities.
Background
In a country as large and diverse as India, the size of the
HIV/AIDS epidemic is difficult to estimate. The most
recent UNAIDS Report on the Global AIDS Epidemic esti-
mated 2.5 million persons were prevalently HIV-infected
as of 2007 [1]. Although HIV prevalence appears to be sta-
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epidemic. Geographically, higher prevalence (2 – 3% of
antenatal women) occurs in south-central and north-east-
ern India (Figure 1), with higher risks in migratory and
underprivileged populations [2]. Transmission in adults is
predominantly heterosexual but injection drug users and
men who have sex with men are also major transmission
groups in some areas. In this report, we summarize what
is known about the cancer experience among Indian per-
sons with HIV/AIDS (PHA).
In the developed countries, the increased cancer risk
among immunosuppressed PHA is well described [3-5]
(Table 1). Kaposi sarcoma (KS) and non-Hodgkin lym-
phoma (NHL) occur at exceptionally high incidence, with
relative risks being 100s-fold above those in uninfected
populations. Cervical cancer is an AIDS-defining cancer
when it occurs in an HIV-infected woman, and the relative
risk is increased 5- to 10-fold [3-5]. Hodgkin lymphoma
is not yet accepted as an AIDS-defining cancer in HIV+
persons, although its risk is increased 10- to 15-fold in
most studies [3-5]. In immunosuppressed PHA, risk of
AIDS-related cancers generally increase with degree of
immunosuppression [6]. However, Hodgkin's lymphoma
incidence has an inverse relationship with CD4 count, in
which moderate decreases in CD4 count greatly increase
risk but risk decreases with severe immunosuppression
[7]. Some tumors are observed more frequently in PHA
because of lifestyles that expose PHA to specific carcino-
gens, such as lung cancer related to the high frequency of
smoking in PHA [8]. A few otherwise rare tumors, such as
squamous cell carcinoma of the conjunctiva [9,10] and
Merkel cell carcinoma of the skin [11], also appear to be
increased. Other tumors have been reported to have mar-
ginal or inconsistent increases in PHA, and their associa-
tions with level of HIV/AIDS immunosuppression are still
controversial. Whether similar associations with cancer
are observed in PHA in India, where infections, genetics,
environmental exposures, and cancer patterns all differ
from developed countries, is unknown. Few studies have
High HIV prevalence areas of IndiaFi ure 1
High HIV prevalence areas of India. Map A. HIV prevalence in India, by district. (Reproduced from Chandrasekaran, et al2, 
with Journal permission.) ANC = Antenatal Clinics. Map B. Cities mentioned in the text. Grey areas indicate where the preva-
lence in women attending antenatal clinics was >1% in 2005 (data approximated from Map A).
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problems.
Current state of knowledge on HIV/AIDS and cancer in 
India
In a review of cancer studies in PHA in 2005 based prima-
rily on retrospective and autopsy data, Chitale[12]
pointed out the paucity of data from India. He estimated
that 3 to 4% of PHA in India will have a cancer during
their course, compared to 34% in the developed coun-
tries. However, cancer incidence in PHA in developed
countries has been driven largely by KS in homosexual
men, a group commonly co-infected with the Kaposi sar-
coma-associated herpesvirus (KSHV). KS appears to be
rare in Indian PHA, and thus the cancer burden in Indian
PHA should be markedly lower.
A report by Dhir et al. [13] provides the only risk estimates
for cancers in HIV-infected persons in India (Table 1).
These authors examined HIV prevalence in persons with
all types of cancer who presented at the Tata Memorial
Hospital, the largest tertiary cancer referral medical center
in India, during 2001–2005. They used proportional inci-
dence ratios (PIR) to assess the likelihood that specific
cancer types were associated with HIV infection, compar-
ing the cancer distribution in PHA to that in the age- and
sex-specific distribution of all cancer patients seen at the
same medical center in 2002. HIV infection was found in
Table 1: Summary of cancers with increased risks in males (M) and females (F) with HIV/AIDS (PHA) in India
Cancer sites 
with 
increased risk
Relative risks 
in developed 
countries
Correlated 
with CD4 loss 
in PHA
Tumor-
associated co-
viral 
infections*
Incidence in 
India, relative 
to developed 
countries
Proportional risk increase in 
Indian PHA [13]
Case 
observations 
in Indian 
PHA**
M F
AIDS-defining 
cancers
Kaposi 
sarcoma
> 1000 ++++ KSHV Rare No cases seen Occasional
Non-
Hodgkin 
lymphoma
20–350 +++ EBV Low 17 10 Multiple
Cervical 
cancer
2–20 - HPV Very high 4 Not reported
Non-AIDS 
defining 
cancers
Anus 20–50 - HPV Low 10 6NS Not reported
Hodgkin 
lymphoma
3–18 Inverse EBV Low 4 2NS Occasional
Vulva and 
vagina
4–8 - HPV High 8 Not reported
Head and 
neck cancers
2–3 - HPV Very high 1NS 2 Not reported
Testis 1–2 - None Low 2 Not reported
NS Not statistically significant
* KSHV: Kaposi sarcoma herpesvirus (Human Herpesvirus 8); EBV: Epstein Barr virus; HPV: Human papillomavirus
** Other than description in risk ratio study [13].Page 3 of 8
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women. KS was not observed, consistent with the general
impression that it is rare in India. In HIV-positive men,
increased PIRs were observed for NHL and Hodgkin lym-
phoma (HL), 17-fold (n = 63) and 4-fold (n = 9), respec-
tively. Five cases of testicular cancer (2-fold PIR) and 10
cases of anal canal cancer were diagnosed (10-fold). In
women, NHL was increased 10-fold (n = 14), while one
case of HL was observed (non-significant 2-fold increase).
Cervical (n = 33) and vulva/vaginal cancer (n = 2) risks
were both increased (4-fold and 8-fold, respectively), and
one anal canal cancer was observed (6-fold increase, not
statistically significant). They also reported marginal
increases in head and neck cancer in both men (46 cases,
1.3-fold, confidence interval: 0.95–1.70) and women (13
cases, 2.3-fold, 1.26–4.12). Of additional interest, they
observed one conjunctival cancer, but the PIR was not
reported. This report provided no data about possible risk
factors such as sexual practices, smoking or chewing
tobacco, or infections.
NHL appears to be the most common type of cancer
reported in Indian PHA. In the Mumbai study [13], NHL
constituted 38% of the cancers seen in male PHA whereas
2% of all cancers were expected on the basis of all patients
in 2002. In female PHA, the proportion of NHL was lower
(16%) than in males because cervical cancer predomi-
nated. Although the most common cancer, it is not a com-
mon cause of lymphadenopathy in PHA. In India,
tuberculosis and other opportunistic infections are major
threats to PHA and far more likely to cause lymphadenop-
athy than cancer. For example, Sharma et al. [14] reported
on 135 consecutive PHA, mostly untreated for HIV infec-
tion, in New Delhi between 2000 and 2003. Among spe-
cifically identified illnesses, tuberculosis dominated
(71%) and co-morbid fungal diagnoses, especially Cand-
ida (39%), were common. In this series, only 2 patients
(1.5%) had lymphoma. In a study of lymphadenopathy
using fine needle aspiration in Mangalore, Shenoy et al.
[15] found lymphoma in 10% of 48 PHA with lymphad-
enopathy, whereas 48% were diagnosed as tuberculosis
and 36% had non-specific causes.
The types of lymphoma occurring among PHA seen at
Tata Memorial Hospital, Mumbai, have been examined by
Agarwal et al. [16] using molecular markers to classify
tumors. Among 35 PHA with lymphoma, they found 24
NHL, 7 HL and 4 plasmocytomas. The NHLs were high-
grade diffuse types consistent with immunoblastic/diffuse
large B cell lymphoma (14 cases) or Burkitt lymphoma (3
cases), the remainder being unspecified. The proportion
of HLs and plasmocytomas in this small study was rela-
tively high compared to that in developed countries. All 7
HL cases were EBV+, which is unusually frequent. In a
study of bone marrow samples from 140 PHA by
Khandekar et al. [17] in Pune, plasmacytosis was a com-
mon feature (86%). However, only one cancer, an immu-
noblastic lymphoma, was observed.
NHL in the central nervous system (CNS) is unusual but
in the developed countries, relative risks are high in PHA,
and the risks increased rapidly as CD4 counts decline [6].
Powari et al. [18] reviewed 40 CNS NHLs in Chandigarh
(North India) from 1985 to 1999, but none of the 14
patients tested was HIV-infected. In a separate study at the
same institute (probably including the same patients),
Tiwari et al. [19] noted CNS NHL incidence increased 10-
fold from the 1970s to 2000. However, HIV prevalence
was low in Chandigarh throughout those years, so the
increase incidence is more likely due to improving diag-
nostic capabilities than increased HIV/AIDS presence. In
Delhi and in Bangalore, Sarkar et al. [20] summarized
CNS NHL cases during 1980–2002, finding few HIV-
infected patients, but neither city had a high HIV/AIDS
prevalence in most of those years.
KS can occur in Indian PHA. In 1993, two reports
described the same case of a 35 year old woman from
Mumbai with multiple lesions who was co-infected with
HIV-1 and -2 [21,22] and other isolated case reports of KS
followed [23,24]. In the National AIDS Control Program,
reports of KS in PHA are uncommon [25]. Gatphoh et al.
[26] followed 26 PHA in Imphal over a three year period,
of whom 4 developed cancer, including two KS, one NHL
and one promyelocytic leukemia. In studies of specific
sites, KS is occasionally reported, but it is more conspicu-
ous by its absence. In a review of pathology submitted on
skin lesion from 134 PHA in Mumbai, Lanjewar et al. [27]
reported 12 (6%) cancers, including 1 KS, 9 squamous cell
carcinomas, and 2 basal cell carcinomas. The majority
(53%) of the patients had infectious conditions. Expected
rates for these cancers were not provided. In an autopsy
study of lung tissues from 97 men and 38 women dying
with HIV/AIDS in Mumbai, Lanjewar and Duggal [28]
found one KS, as well as one squamous cell lung cancer.
None had NHL. In their review of oral lesions in PHA,
Ranganathan and Hemalatha [29] reported no cases with
KS in HIV/AIDS patients from Chennai. Biswas et al. [30]
followed 100 PHA attending an eye clinic in Chennai
between 1993 and 1998 but observed no cancers. Simi-
larly, Gharai et al. [31] reported no eye cancers in 100 con-
secutive PHA attending an eye clinic in New Delhi.
In the Mumbai study [13], cervical cancer was the most
common cancer (39%) in women. However, other than
in this report, cervical cancer risk in PHA has not been
reported in India. In Pune, Joshi et al. [32] reported on
287 consecutive HIV-infected Indian women who under-
went screening, finding 6.3% to have dysplasia but none
had cancer. No data were provided about expected rates ofPage 4 of 8
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comparable age.
Discussion
As elsewhere, cancer is a health concern in the general
population of India, where approximately 750,000 can-
cers are diagnosed annually [33]. The current review of the
data available about cancer in PHA in India highlights the
paucity of information in these high-risk persons. The
studies are limited in number and duration and have few
outcomes. The published studies include almost no
assessment of risk factors which might affect cancer risks
in PHA. In the general population of India, the patterns of
diagnosed cancer differ from those in the developed coun-
tries, indicating risk factors for cancer in India differ from
those in developed countries. Thus, the cancer profile in
Indian PHA may also differ from that in the developed
countries.
While the studies we reviewed suggest that cancer is not
currently a common clinical problem, it is reasonable to
speculate that competing mortality from infectious prob-
lems, particularly tuberculosis and fungal infections, has
truncated survival, preventing progression to severe
immunosuppression when risks for common cancers like
NHL and KS increase. However, India is emerging as a
leader in developing affordable regimens of highly active
antiretroviral therapy to control HIV replication and drugs
to treat infectious conditions. The application of these
treatments will reduce the effects of competing mortality
and likely amplify the importance of cancer in PHA. An
AIDS-cancer record linkage between available registries in
overlapping areas will be of great help in monitoring the
changing relationship between AIDS and cancer incidence
during a time when treatments become increasingly used.
As in the developed countries, the most important AIDS
cancer type in India is NHL, perhaps affecting 2% of
Indian PHA [12]. Prior to effective antiretroviral therapy,
about 6% of AIDS cases in developed countries were
expected to have NHL, either at AIDS onset (3%) or dur-
ing their AIDS course (3%) [3]. NHL risk is higher when
immunosuppression is severe [6], and competing mortal-
ity from other infections in PHA will strongly affect sur-
vival time and therefore the likelihood of developing
NHL. Thus, with strong competing risks of mortality, per-
haps 2% of Indian PHA ever having NHL is a reasonable
estimate. The lack of CNS NHL associations so far
reported may be only because studies examining this
question have been conducted in areas where HIV preva-
lence was low in those years. Additionally, CNS NHL risks
increase in severely immunosuppressed persons [6], but
these PHA may have limited survival because of infec-
tions. However, if risk is not increased, it would be useful
to understand why. The NHL histology appears to be typ-
ical of that seen in the developed countries, with most
being immunoblastic/large cell diffuse lymphomas. Based
on limited data, Burkitt lymphoma is not common, which
is surprising since Burkitt lymphoma occurs in PHA with
relatively high CD4 count [6]. In contrast, plasmacytomas
may be somewhat more frequent than expected. Relative
to NHL, HL may be more frequent than expected and also
more likely to be associated with EBV. However, in devel-
oped countries, HL tends to be more frequent when PHA
are not profoundly immunosuppressed [7], which may
explain the increased proportional frequency in a popula-
tion with limited survival after AIDS onset.
In India, KS is uncommon. KSHV infection is required for
KS to develop, and population variations in KS incidence
seem to reflect differences in the prevalence of KSHV.
Although KS can occur without severe immunosuppres-
sion, the risk increases progressively as CD4 counts
decline [6]. However, given the presence of KSHV infec-
tion, KS risk is high in PHA, even when CD4 counts are
only modestly low. In developed countries, KSHV occurs
predominately in men who have sex with men (30%
infected compared to 1–3% infected in other groups) [3].
For unexplained reasons, there appears to be little KSHV
infections in India (7% in a general population [34]) or
elsewhere in Asia, at least relative to Africa. Additional
studies are needed to confirm this finding, especially in
men who have sex with men.
Assuming it is confirmed that KSHV is uncommon in
India, why would this be so? The west coast areas of India,
in particular, have had many centuries of immigration
and trade interaction with east and central Africa, where
half or more of adults are KSHV-infected and KS is also
endemic [35]. In Africa, KSHV prevalence increases rap-
idly in both sexes from early childhood, particularly in
poorer households without access to clean water. Trans-
mission is probably via saliva exchange [36]. Yet, in India
or other areas of Asia, KSHV has not spread, despite a large
population living in poor socioeconomic conditions and
lack of access to water. Additionally, studies elsewhere
have found pockets of KSHV in unexpected places, such as
among Amerindians in the Amazon Basin [37]. Might
such pockets exist elsewhere, such as among minorities in
the more remote rural areas of India? Analysis of KS data
from the National AIDS Control Organization may sug-
gest places or subpopulations where KSHV is present.
Human papillomavirus is associated with a variety of ano-
genital cancers and appears to be an important contribu-
tor to cancer risk in India. Cervical cancer incidence is
among the highest in the world, and vulva/vaginal, anal
and penile cancers all have a relatively high incidence
[33]. Their risk appears to be even higher in India PHAs
[13]. Similar associations have been made in the devel-Page 5 of 8
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much lower [38-40]. However, the role of HIV infection
and immunosuppression in cancer causation is controver-
sial because both HPV and HIV are similarly sexually
transmitted, making if difficult to exclude confounding
due to sexual behaviors. In Indian PHA, studies are
needed to examine sexual behaviors in the context of the
occurrence of these cancers. A specific role for HIV and
immunosuppression in cervical cancer occurrence is
favored by reported associations between HIV infection
and high grade dysplasia at these sites in the developed
countries [38-40]. However, against a specific association
with HIV, cervical cancer incidence was not increased in
unscreened African women despite a major HIV/AIDS epi-
demic in this population [41]. Furthermore, the risk of
invasive cervical cancer in women with AIDS does not cor-
relate with the degree of immunosuppression [6]. One
explanation is that women in areas with limited medical
care have a high competing mortality and die before dys-
plasia can progress to cervical cancer. As Indian PHA sur-
vive longer, these cancers could become increasingly
important, making screening PHA for pre-cancerous
lesions a high public health priority.
Among other cancers, the 2-fold increased risk of head
and neck cancer in India [13] is concerning. This cancer is
one of the most common in India [33], and small relative
risk increases in PHA would have important public health
consequences. However, evidence of an association is
weak. Notably, the increases were mainly at buccal/palatal
sites which are specifically associated with chewing
tobacco and betel nut rather than at pharyngeal and ton-
sillar sites, which are HPV-associated. In India, tobacco
and betel chewing are widely practiced, albeit less fre-
quently in recent years [42]. Specific risk factor studies will
be required to clarify if the risk in Indian PHA is increased
after adjustment for this exposure, which could well differ
between PHA and the general population.
Cancer risk at other or unexpected sites appears to be little
increased in Indian PHA. When increases are reported,
much of the association is likely to be because of con-
founding rather than a direct HIV or immunosuppression
effect. The 2-fold higher risk of lung cancer in Indian PHA
is likely explained by an increased frequency of smoking
[7]. Similarly, marginally significant increases in liver can-
cer risk (3-fold risk; 95% confidence interval: 0.96–9.26)
[13] may be because both HIV and hepatitis viruses B and
C are transmitted through needle sharing in drug users
and blood product use [43]. Conjunctiva tumor risk could
be increased because, for reasons of occupation, ultravio-
let light exposure is more common in PHA [9]. The excess
risks of other rare tumors are small, and it is difficult to
determine if exposures in PHA might be different from
those in the general population because their etiologies
are not known. Although based on few cases, the 2-fold
increase in testicular cancer in Indian PHA [13] is interest-
ing since the incidence of this cancer was, until the mid
1990s, also marginally increased in the developed coun-
tries [44]. No risk factors are known to be associated with
testicular cancer.
Studies in places like India, where environmental expo-
sures differ greatly in different populations, offer new
opportunities to identify novel associations or clarify risk
factors. Finding new associations is of general scientific
interest. The recent finding of a polyomavirus associated
with Merkel cell carcinoma [45], an HIV/AIDS related
tumor [11], demonstrates the potential for discovering
new viral associations. Careful clinical study of PHA
among isolated populations, such as Hill Tribes, might
lead novel insights about cancer associations. Similarly,
some areas of India have specific parasitic problems (e.g.,
schistosomiasis or leishmaniasis) that might result in
unique clinical manifestations in PHA. The chronic irrita-
tion resulting from poor control of such infestations in
PHA hypothetically could result in cancer, such as of the
bladder or lymphoid organs. There are therefore many
opportunities for the alert clinician to generate new obser-
vations.
Clearly, prevention of HIV infection must be the highest
public health priority in India. For PHA, HIV infection has
already occurred. In them, reducing mortality from pre-
ventable infections like tuberculosis and Candida is the
primary priority. However, success in these goals will
reveal new clinical challenges, including from cancer.
Thus, India stands at a crossroads where knowledge about
cancer in PHA is likely to contribute to understanding
cancer itself and may also provide data to develop public
health responses to the emergent problem. The renewed
focus on HIV/AIDS care in India makes cancer monitoring
and research in PHA timely. In this context, systematic
gathering of treatment outcome data for cancers in PHA
and comparing response and survival to cancers in non-
HIV infected population is essential. Such data will allow
the development of treatment regimens that might best be
suited to PHA in India and permit the investments in
antiretroviral therapy to be meaningful to all PHA.
Research can provide practical as well as academic bene-
fits, informing both health care and the public health
planning. These studies also encourage the development
of epidemiology and laboratory capability. Indian
researchers should focus on the advantages conferred by
undertaking studies that might be uniquely done in their
own context and are likely to have public health relevance
to India.Page 6 of 8
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